The news came days after shares of GlaxoSmithKline Plc, Sanofi SA, Pfizer Inc, and Haleon Plc were hit by mounting investor concern about thousands of lawsuits claiming the drug, which U.S. regulators pulled from the market in 2020, causes cancer.
Shares in GSK, Sanofi, Haleon, and Pfizer began to recover on Friday after the companies said that nothing material had changed regarding U.S. litigation focused on heartburn drug Zantac.
The company’s blockbuster cancer drug, in combination with chemoraditation therapy showed improvement in event-free survival, but the results did not meet statistical significance.
A federal appeals court on Tuesday revived a lawsuit by a Georgia man claiming Bayer AG’s Roundup weedkiller caused his cancer, the latest in a string of legal defeats for the company as it seeks to avoid potentially billions of dollars in damages.
DEM BioPharma, backed by an impressive list of investors, debuted Thursday with $70 million that will assist in its efforts to treat cancer with an approach that leverages CRISPR screening and macrophage biology in immuno-oncology.
A U.S. jury found Bayer’s Roundup weedkiller did not cause an Oregon man’s cancer, the German agriculture and pharmaceuticals company said on Saturday, handing the firm its fourth consecutive trial victory over such claims.
The U.S. Centers for Disease Control and Prevention (CDC) said it was awarding $215 million in first-year funding as part of reviving the erstwhile Obama administration’s Cancer Moonshot initiative aimed at prevention and control of the disease.
The U.S. Food and Drug Administration (FDA) is on a mission to recover from the review lag seen through the early years of COVID-19 and has issued special designations for two treatments that could improve the lives of millions diagnosed with recurrent glioblastoma or hemophilia.
The American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC) are combining their efforts to increase racial and ethnic diversity in clinical trials.
The U.S. biotechnology arena is undergoing a record-breaking M&A cycle for the industry. After generating M&A activity valued at $235 billion during 2014, the U.S. biotech sector produced more than $100 billion in deals during first-quarter 2015.